This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
The standardization of products for the treatment of pernicious anemia is defined for the first time by the Eleventh Revision of the United States Pharmacopeia as follows: "Liver, stomach and other preparations used for this purpose, to be recognized as meeting the specifications of this Pharmacopeia, must be approved by the 'U. S. P. Anti-Anemia Preparations Advisory Board.' Approved products must have complied with the following specifications: 1. There shall have been submitted from time to time, as requested by the board, satisfactory clinical data from treatment, with the product in question, of cases of addisonian pernicious anemia. 2. The clinical data submitted shall satisfy the U. S. P. Anti-Anemia Preparations Advisory Board that the administration of the material in question, as prepared from liver or stomach, can produce a satisfactory result in the dose given."
In accordance with this requirement, the U. S. P. Anti-Anemia Preparations Advisory Board has
. REPORT ON POTENCY OF LIVER PRODUCTS. JAMA. 1938;110(11):812. doi:10.1001/jama.1938.62790110014009a
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: